TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04539340

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: GNR-055
Description: Single intravenous administration

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: GNR-055
Description: Single intravenous administration

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: GNR-055
Description: Single intravenous administration

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: GNR-055
Description: Single intravenous administration

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: GNR-055
Description: Single intravenous administration
Study: NCT00360594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acamprosate
Description: 3 pills (666 mg) for 1998mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 pills (666mg) for 1998mg/day
Study: NCT02318667

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Golimumab 50mg/0.5 mL in a single-use, ready-to-use autoinjector. Golimumab is a fully human anti-TNF (tumor necrosis factor) alpha monoclonal antibody that will be administered SC.
Study: NCT02244216

Intervention type: DRUG
Intervention: Berotec® N 100 µg Metered-dose Inhaler
Study: NCT02466711

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Relamorelin
Description: Double blind RM-131 will be delivered three times by injection during the course of the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double blind Placebo will be delivered three times by injection during the course of the study
Study: NCT01441830

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radial extracorporeal shock wave therapy
Description: The shockwave treatment will be administered once a week for four weeks on one to three specific points (supraspinatus, infraspinatus or subscapular tendon)and with a pressure between 1,5-3 Bar

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Radial extracorporeal shock wave therapy
Description: The shockwave treatment will be administered once a week for four weeks on one to three specific points (supraspinatus, infraspinatus or subscapular tendon)and with a pressure between 1,5-3 Bar
Study: NCT02347098

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intensive LDL-lowering therapy
Description: The intensive LDL-lowering therapy uses LDL-apheresis in addition to the standard statin therapy. The device used in this study is the LIPOSORBER LA-15 System, manufactured by Kaneka Pharma America LLC. A filter separates plasma from whole blood, the Liposorber -columns remove LDL from the plasma. The system recombines plasma and blood cells and returns them into the patient's body. This procedure typically takes about 3 hours. The procedure provides an immediate reduction in a patient's lipid levels. A single apheresis treatment can lower LDL by more than 80%, but levels return to baseline within 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard statin monotherapy
Description: The standard statin therapy of 40-80mg oral daily dose of Atorvastatin or other equivalent types of statin to lower LDL in blood for both randomized groups.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard statin monotherapy
Description: The standard statin therapy of 40-80mg oral daily dose of Atorvastatin or other equivalent types of statin to lower LDL in blood for both randomized groups.
Study: NCT02424942

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form:solvent for parenteral use~Route of administration: intraarticular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZ389988
Description: Pharmaceutical form:suspension for injection~Route of administration: intraarticular
Study: NCT00128856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study: NCT02861209

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of a care pathway
Description: The care pathway will consist of procedures of care in the hospital (e.g. consultations with doctors, contact moments with nurses, ...) that describe the initiation of an oral anticancer therapy and the further follow up. The care pathway should describe how care can efficiently be organised.
Study: NCT02744443

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05698082

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Immunohistochemical staining with anti-FOS
Description: The tissue sections were incubated with anti-FOS (promab 30360) at 4ºC overnight and washed three times with PBS. After that, it is required that incubation with secondary anti-peroxidation sunflower at 37ºC for 30 minutes. After washing three times again with PBS, the sections were developed in diaminobenzidine and microscopic images were made by light microscopy.
Study: NCT03187938

Intervention type: DIAGNOSTIC_TEST
Intervention: Testing of Alkaline Phosphatase Levels
Description: Testing of alkaline phosphatase levels at the time of the 24w0d to 28w6d week labs.
Study: NCT03922386

Intervention type: DEVICE
Group type: OTHER
Intervention: XFINE leads
Description: Pacemaker subjects with at least one XFINE passive lead

Intervention type: DEVICE
Group type: OTHER
Intervention: XFINE leads
Description: Pacemaker subjects with at least one XFINE passive lead
Study: NCT03622489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: mentioned above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: mentioned above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: mentioned above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Description: mentioned above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Description: mentioned above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Description: mentioned above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipyrone
Description: mentioned above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: mentioned above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: mentioned above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: mentioned above
Study: NCT01989403

Intervention type: OTHER
Intervention: herbal medicine, acupuncture, bee-venom acupuncture, and Chuna manipulation
Study: NCT01528111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX7101 (0.125%)
Description: Subjects will receive 0.125% LX7101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX7101 (0.25%)
Description: Subjects will receive 0.25% LX7101

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LX7101 Vehicle
Description: Subjects will receive vehicle
Study: NCT04315675

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Imagery Intervention
Description: The participant listens to a selected Guided Imagery for 21 consecutive days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Power Intervention
Description: The participant develops a plan to achieve healthy outcomes and reviews plan for 21 consecutive days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Guided Imagery and Cognitive Power Intervention
Description: The participant completes 21 days of selected Guided Imagery in combination with the development of a plan to achieve healthy outcomes and reviews the plan for 21 days.
Study: NCT03329911

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU Avastin®
Description: 100 mg/4 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1706
Description: 100 mg/4 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 200 mg/m²

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 200 mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: target area under the curve \[AUC\] 6 mg/mL•minute

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: target area under the curve \[AUC\] 6 mg/mL•minute
Study: NCT01563770

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salvia miltiorrhiza extract
Description: 3 capsules of 500 mg Salvia miltiorrhiza extract, twice daily for four consecutive weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 placebo capsules, twice daily for four consecutive weeks
Study: NCT02907294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-999 / 160 mg
Description: 2 capsule 80 mg x 8 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-999 / 320 mg
Description: 4 capsule 80 mg x 8 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules of placebo x 8 days 4 capsules of placebo x 8 days
Study: NCT01334151

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin LISPRO
Description: Single doses of: 0.15 U/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human insulin
Description: Single doses of: 0.15 U/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human insulin
Description: Single doses of: 0.15 U/kg
Study: NCT00129324

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lead Hazard Control Intervention
Description: Prior to their child's birth, participants randomized to Lead Reduction Group received lead hazard reduction controls to reduce residential exposure to lead.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Injury Hazard Control Intervention
Description: Between 3 and 6 months of age, participants randomized to Injury Reduction Arm received injury hazard controls to reduce the number of residential injuries.
Study: NCT03799250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringer lactate
Description: Comparison between fluid maintenance in PACU compared to a bolus based goal directed hemodynamic therapy in the PACU

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: standard care
Study: NCT01610180

Intervention type: DRUG
Group type: OTHER
Intervention: Eltrombopag Olamine
Description: Initial dose : 50 mg/day for 14 days.~Next doses:~1. If platelet count \<60000/µL, increase daily dose by 25 mg to a maximum of 150 mg/day for next 14 days in 14 days courses. If response criteria not met after 14 days of the maximum dose stop treatment (no response).~2. If platelet count \>60000/µL and ≤200000/µL same dose for the next 14 days.~3. If platelet count \>200000/µL and ≤400000/µL decrease the daily dose by 25 mg. Wait 14 days to assess the effects of this and any subsequent dose adjustments.~4. If platelet count \>400000/µL, stop Eltrombopag; increase the frequency of platelet monitoring to twice weekly. Once the platelet count is \<150000/µL, reinitiate therapy at a daily dose reduced by 25 mg.
Study: NCT01838109

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral nutritional supplement
Study: NCT01372384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150 mg orally daily
Study: NCT03410173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taurine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02701543

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ranger Drug Eluting Balloon
Description: Percutaneous transluminal angioplasty (PTA), in which a balloon is advanced and inflated in the obstructed artery for several seconds to minutes, has become the standard endovascular treatment for peripheral arteries

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: In Pact Drug Eluting Balloon
Description: Percutaneous transluminal angioplasty (PTA), in which a balloon is advanced and inflated in the obstructed artery for several seconds to minutes, has become the standard endovascular treatment for peripheral arteries
Study: NCT04360551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 40mg
Description: Angiotensin Receptor Blocker (ARB)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily
Study: NCT03219242

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Caiman® device
Description: Using CAIMAN device in primary surgery for ovarian cancer. Analyze potential time-sparing and the incidence of post-surgical complications.
Study: NCT00960661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (26 weeks), twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin lispro
Description: titrated based on pre-meal glucose level; three times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin/ Glargine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin/ Glargine
Study: NCT02770547

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Heat Thermotherapy
Description: Subject will wear a High Density LCG (Liquid Circulating Garment). Water will be heated and circulated through the garment, which in turn supplies low heat to the subject's leg.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Heat Thermotherapy
Description: Subject will wear a High Density LCG (Liquid Circulating Garment). Water will be heated and circulated through the garment, which in turn supplies high heat to the subject's leg.
Study: NCT00859378

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cemented semiendoprosthesis
Description: Application of a cemented semiendoprosthesis (Basis, Smith \& Nephew)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-cemented
Description: Patients are treated with a non-cemented semiendoprosthesis (Biomet Taperloc, Biomet Inc.)
Study: NCT03134599

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: methafilcon A - Interozzo
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: methafilcon A - CVI (CooperVision)
Description: contact lens
Study: NCT03385811

Intervention type: OTHER
Intervention: no intervention, only questionnaires survey
Description: questionnaires survey
Study: NCT02031497

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Drink with sweeteners
Description: Subjects will have to consume a 330ml can of a drink with sweeteners twice per day as part of their usual fluid intake for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Drink with sweeteners
Description: Subjects will have to consume a 330ml can of a drink with sweeteners twice per day as part of their usual fluid intake for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Drink without sweeteners
Description: Subjects will have to consume a 330ml can of a drink without sweeteners twice per day as part of their usual fluid intake for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Drink without sweeteners
Description: Subjects will have to consume a 330ml can of a drink without sweeteners twice per day as part of their usual fluid intake for 12 weeks.
Study: NCT02376270

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pectin
Description: This group will receive 7.5 grams of pectin supplements twice daily for four weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: This group will receive 7.5 grams of maltodextrin supplements twice daily for four weeks.
Study: NCT03546530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon
Description: Interferon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon+resveratrol
Description: Interferon+resveratrol
Study: NCT01972620

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: A 50:50 mixture of normal saline (8 ml) and 0.5% Bupivacaine was prepared within a 20 ml syringe (Total volume 16 ml; Final concentration = 0.25%). Following delivery of the gallbladder specimen in the Multi-modal analgesia group, 8 ml of 0.25% bupivacaine solution was sprayed onto the cystic plate (gallbladder fossa) with a spinal needle advanced under direct laparoscopic vision via a 5mm right subcostal laparoscopic port. The anesthetic solution was sprayed at an operating distance from the cystic plate of \~ 2 cm. Following evacuation of the pneumoperitoneum, again within the Multi-modal analgesia group, the remaining 8 ml of 0.25% Bupivacaine was infiltrated subcutaneously at each of the four laparoscopic port sites (2 ml per port site) prior to standard sutured closure of each incision
Study: NCT02840695

Intervention type: DRUG
Intervention: bDMARD treatment
Description: Treatment with bDMARD includes registered ATC-codes: L04AA and L04AB.
Study: NCT01392534

Intervention type: DRUG
Intervention: Telmisartan/hydrochlorothiazide (Pritor Plus, BAY98-7103)
Description: Patients treated with telmisartan/hydrochlorothiazide tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
Study: NCT00918034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: talaporfin sodium
Description: LS11 (talaporfin sodium) dose of 1mg/kg will be administered intravenously by slow push (3-5 minutes)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transurethral illumination with light emitting diodes
Description: A light dose of 100 Joules per centimeter (J/cm) will be delivered at 20 mW/cm to each patient for a treatment duration of 1 hour 23 minutes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement
Description: Placement of device in prostate urethra
Study: NCT02162524

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: The exercise groups will be closely monitored during exercise sessions for six months in our exercise-training laboratory. The intensity will be 65% VO2peak and all exercise will occur on a treadmill. One exercise group will obtain 8 KKW (kcal/kg/week) over 3-4 sessions per week, which will result in each session lasting approximately 30 minutes. The other exercise group will obtain 20 KKW, performing 4-5 sessions per week for approximately 50-70 minutes per session. These groups are combined for this ancillary study.
Study: NCT00861068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPM927/Lacosamide
Description: SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 600mg/day, intake in the morning and in the evening, intake for 11 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets two times a day for 10 weeks
Study: NCT03014778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The Chlorhexidine gluconate 0.05%
Description: Washing vagina pre- operatively with Chlorhexidine gluconate 0.05%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10% Povidone iodine
Description: Washing vagina pre- operatively with 10% Povidone iodine
Study: NCT02512471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: brachial plexus block with ropivacaine 0.275%, MEV90 for USG-SCB (young group) brachial plexus block with ropivacaine 0.325%, MEV90 for USG-SCB (middle-aged group)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: brachial plexus block with ropivacaine 0.275%, MEV90 for USG-SCB (young group) brachial plexus block with ropivacaine 0.325%, MEV90 for USG-SCB (middle-aged group)
Study: NCT03108547

Intervention type: OTHER
Intervention: Determination of scalp hair steroids

Intervention type: OTHER
Intervention: Determination of scalp hair steroids

Intervention type: OTHER
Intervention: Determination of scalp hair steroids
Study: NCT00185744

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intra-Operative Radiotherapy (IORT)
Description: single dose in the operating room after lumpectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumpectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumpectomy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole Breast Radiotherapy
Description: six and a half week treatment

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intracavitary Brachytherapy
Description: 5 day treatment

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated External Beam 3-D Conformal Radiotherapy
Description: 5 day treatment

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic APBI
Description: 4 day treatment
Study: NCT01152320

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spirometry Fundamentals™ Training CD
Description: MD-MA pairs randomized to the intervention arm of the study received 2 copies of the Spirometry Fundamentals™ CD. Included with the CDs was a letter explaining that each member of the MD-MA pair should view the CD at their convenience within the following 3 weeks. This letter included instructions on how to access the study website in order to complete an evaluation survey after viewing the CD.
Study: NCT03978507

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intelligent cueing
Description: 1 month use of an intelligent, wearable device that provides personalized cueing only when FOG is detected

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Feedback about the number of steps
Description: Feedback about the number of steps is given in the intervention group as well as in the control group during the 1-month intervention-period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback about the number of steps
Description: Feedback about the number of steps is given in the intervention group as well as in the control group during the 1-month intervention-period.
Study: NCT01244555

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: Twice weekly ultrasound sessions for 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage
Description: Twice weekly massage sessions for 6 weeks
Study: NCT05530603

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational mobile app
Description: 7 day educational course to educate American Indian women to receive regular mammogram.
Study: NCT01545479

Intervention type: DRUG
Group type: OTHER
Intervention: captopril 25mg
Description: renal blood oxygenation after captopril